Welcome to our dedicated page for Precision Biosciences SEC filings (Ticker: DTIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Precision BioSciences, Inc. filings document regulatory disclosures for a clinical-stage gene editing company built around the ARCUS platform and in vivo therapeutic candidates. Recent Forms 8-K furnish operating results, financial-condition updates, business presentations, and Regulation FD materials covering PBGENE-HBV in chronic hepatitis B and PBGENE-DMD in Duchenne muscular dystrophy, including IND-related and clinical-development disclosures.
The company’s proxy materials address board and stockholder meeting matters, executive compensation, equity plans, and governance proposals. Other filing categories cover material agreements, shareholder voting matters, capital-structure disclosures, inducement awards, and forward-looking risk language tied to clinical development, financing capacity, regulatory review, and public-company reporting.
Precision BioSciences Chief Financial Officer John Alexander Kelly reported routine equity compensation activity. On January 20, 2026, previously granted Restricted Stock Units vested, resulting in the delivery of 3,888, 13,900, and 26,575 shares of common stock, each RSU converting into one share. On January 21, 2026, Kelly sold 15,213 shares of common stock at $4.03 per share under a pre-established Rule 10b5-1 trading plan. The sale was a sell-to-cover transaction, with shares sold only to cover tax withholding obligations and related fees tied to the RSU vesting. After these transactions, Kelly directly held 106,448 shares of Precision BioSciences common stock.
Precision BioSciences Chief Research Officer J. Jefferson Smith reported RSU vesting and a related tax sale. On January 20, 2026, RSUs covering 2,500, 10,447, and 16,219 shares vested, each RSU representing one share of common stock. On January 21, 2026, Smith sold 10,200 shares of common stock at $4.03 per share under a pre-arranged Rule 10b5‑1 plan as a sell‑to‑cover transaction for tax withholding tied to the RSU vesting.
Following these transactions, Smith directly owned 110,184 shares of Precision BioSciences common stock and held an additional 7,931 shares indirectly through a charitable remainder unitrust. RSU holdings after the transactions included 10,447 and 16,219 units that remain subject to their vesting schedules.
Precision BioSciences plans an insider stock sale under Rule 144. A holder intends to sell 34,799 shares of DTIL common stock through Fidelity Brokerage Services LLC on or around 01/22/2026, with an indicated aggregate market value of $145,202.30. The shares are listed on the NASDAQ.
The securities to be sold were acquired on 01/20/2026 through restricted stock vesting from the issuer as compensation. The filing also notes that Michael Amoroso sold 3,409 common shares on 11/03/2025 for gross proceeds of $22,121.00. The signer represents that they are not aware of undisclosed material adverse information about the company’s operations.
Precision BioSciences, Inc. is the subject of a Schedule 13G reporting that investment manager Empery Asset Management, LP and Ryan M. Lane beneficially own 2,297,781 shares of its common stock, equal to 9.99% of the outstanding class. This total includes 103,146 shares issuable upon exercise of warrants, calculated using 22,897,665 shares of common stock outstanding as of November 10, 2025.
The filing explains that the warrants are subject to a 9.99% “Blocker,” which prevents the reporting persons from exercising warrants to the extent such exercise would push their beneficial ownership above 9.99%. Empery acts as investment manager to the funds that hold the shares and warrants, and Lane is described as an individual with indirect control over the investment manager. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of Precision BioSciences.
An insider of DTIL filed a notice of proposed sale under Rule 144 for 8,854 common shares, with an aggregate market value of 35,653.29. The shares are expected to be sold on 01/21/2026 on the NASDAQ through Fidelity Brokerage Services LLC. These shares were acquired on 01/20/2026 through restricted stock vesting from the issuer as compensation, rather than a cash purchase. The filing also reports that Dario J. Scimeca previously sold 665 common shares on 11/03/2025 for gross proceeds of 4,315.19. By signing the notice, the seller represents they are not aware of undisclosed material adverse information about the issuer’s operations.
DTIL received a Rule 144 notice for a planned sale of 10,200 shares of its common stock through Fidelity Brokerage Services LLC on 01/21/2026, to be sold on NASDAQ with an aggregate market value of $41,073.36. These shares were acquired from the issuer on 01/20/2026 through restricted stock vesting as compensation on the same date. The filing notes that the seller represents they are not aware of any material adverse, non-public information about the issuer’s current or prospective operations.
A stockholder of DTIL filed a Rule 144 notice to sell 15,213 common shares, with an aggregate market value of $61,259.71. The proposed sale is through Fidelity Brokerage Services on the NASDAQ, with an approximate sale date of 01/21/2026, and the form notes 13,256,751 shares outstanding. The shares to be sold were acquired on 01/20/2026 through restricted stock vesting from the issuer as compensation. The filing also reports that during the past three months, a holder named John A. Kelly sold 1,303 common shares for gross proceeds of $8,455.17.
Precision BioSciences reports preliminary year-end liquidity and key clinical timelines. The company expects to report approximately $137 million in cash, cash equivalents and restricted cash as of December 31, 2025, based on unaudited, still-subject-to-change figures. It believes that existing cash, potential near-term consideration from license partners, continued fiscal discipline and access to its at-the-market facility together should extend its cash runway through 2028.
The company also outlines upcoming milestones for its gene-editing programs. For the ELIMINATE-B trial of PBGENE-HBV, additional biopsy data are expected in the first half of 2026, with completion of dosing in Cohorts 3, 4 and 5, selection of an optimal dose regimen to stop nucleos(t)ide analog therapy, and initiation of Part 2 expansion. Pending investigational new drug clearance, the FUNCTION-DMD Phase 1/2 trial in Duchenne muscular dystrophy is expected to dose its first patient in late-Q1 or early-Q2 2026, with initial data from multiple patients anticipated by year end 2026.
Precision Biosciences Inc. director Geno Germano reported an open-market purchase of the company’s common stock. On 12/16/2025, he bought 3,000 shares of common stock at a weighted average price of $4.72 per share, with individual trade prices ranging from $4.718 to $4.720.
Following this transaction, Germano beneficially owns 23,883 shares of Precision Biosciences common stock in direct ownership.